A LAG-3, Op­di­vo com­bo from Bris­tol-My­ers of­fers a proof-of-con­cept glimpse of lim­it­ed suc­cess

CHICA­GO — Now that the first wave of PD-(L)1 drugs has splashed out and is get­ting es­tab­lished in the can­cer mar­ket, one of the next …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.